B of A Securities Upgrades Candel Therapeutics to Buy, Raises Price Target to $18
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral to Buy and raises the price target from $12 to $18.
B of A Securities analyst Alec Stranahan upgrades Candel Therapeutics (NASDAQ:CADL) from Neutral to Buy and raises the price target from $12 to $18.